Atomoxetine: Treatment of attention-deficit/hyperactivity disorder through selective norepinephrine reuptake inhibition

Christopher J. Kratochvil, Martin J. Harrington, William J. Burke, Brigette S. Vaughan

Research output: Contribution to journalReview articlepeer-review


Atomoxetine (Strattera™), a selective norepinephrine reuptake inhibitor, is the first non-stimulant to be approved for treating attention-deficit/hyperactivity disorder (ADHD). It is the only medication that has received FDA approval for use in adults as well as children with this condition. The results of 9 clinical trials of atomoxetine, including a number of double-blind, placebo-controlled multicenter studies, have demonstrated its high degree of efficacy in controlling the symptoms of ADHD, and favorable patient tolerability, in children, adolescents and adults. While most of the clinical trials employed a twice-a-day dosing schedule, a single daily dose has been shown to be equally efficacious and safe. Transient gastrointestinal side effects were most frequently reported, which in most cases did not lead to discontinuation of atomoxetine therapy. Additional long-term studies are ongoing; direct comparison trials with stimulant agents, and evaluations of atomoxetine in ADHD patients with co-morbid conditions such as substance abuse, depression, anxiety and tics, are warranted to explore the potential for further expanding the use of this novel medication.

Original languageEnglish (US)
Pages (from-to)239-250
Number of pages12
JournalToday's Therapeutic Trends
Issue number3
StatePublished - Sep 2003

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Atomoxetine: Treatment of attention-deficit/hyperactivity disorder through selective norepinephrine reuptake inhibition'. Together they form a unique fingerprint.

Cite this